etoposide has been researched along with Adrenocortical Carcinoma in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.86) | 18.2507 |
| 2000's | 11 (31.43) | 29.6817 |
| 2010's | 14 (40.00) | 24.3611 |
| 2020's | 9 (25.71) | 2.80 |
| Authors | Studies |
|---|---|
| Kojima, Y; Maeshima, AM; Nishikawa, T; Noguchi, E; Shimoi, T; Sudo, K; Tanioka, M; Uchihara, M; Yonemori, K | 1 |
| Feng, C; Li, K; Li, N; Li, Y; Lyu, Y; Wang, L; Wen, H | 1 |
| Iinuma, K; Kato, D; Kawase, K; Kawase, M; Koie, T; Miyazaki, T; Nakai, C; Nakane, K; Namiki, S; Takai, M; Takeuchi, S; Takeuchi, Y; Tsuchiya, T; Ueda, S | 1 |
| Abate, A; Berruti, A; Cosentini, D; Cremaschi, V; Grisanti, S; Laganà, M; Rossini, E; Sigala, S; Tamburello, M; Turla, A | 1 |
| Berruti, A; Gregory, SN; Habra, MA; Hernandez, JM; Sarvestani, AL; Teke, ME; Terzolo, M | 1 |
| Fan, XX; Li, ZH; Wang, L; Wang, XY; Weng, Y; Yan, L; Zhang, SL | 1 |
| Altieri, B; Fassnacht, M; Kroiss, M; Ronchi, CL | 1 |
| Chen, TC; Dai, SH; Tsai, WH; Zeng, YH | 1 |
| Berruti, A; Carminati, O; Cosentini, D; Ferrari, VD; Grisanti, S; Laganà, M; Rosti, G; Sigala, S; Turla, A | 1 |
| Albany, C; Chovanec, M; Hahn, N; Taza, F | 1 |
| Das, A; Shuayb, M; Uddin, MN | 1 |
| Assie, G; Baudin, E; Berruti, A; de Krijger, R; Dekkers, OM; Else, T; Fassnacht, M; Haak, HR; Mihai, R; Terzolo, M | 1 |
| Beuschlein, F; Hantel, C; Jung, S; Mussack, T; Reincke, M | 1 |
| Beuschlein, F; Fassnacht, M; Hantel, C; Igaz, P; Jung, S; Nagy, Z; Reincke, M; Weiss, M; Zambetti, G | 1 |
| AbAziz, A; Kamaruddin, NA; Mustafa, N; Sukor, N; Wahab, NA; Zainudin, S | 1 |
| Balasubramaniam, S; Bates, SE; Edgerly, M; Fojo, T; Leuva, H; Litman, T; Merino, MJ; Payabyab, EC; Velarde, M; Venkatesan, AM | 1 |
| Beuschlein, F; Bidlingmaier, M; Chiapponi, C; Hantel, C; Jung, S; Luconi, M; Poli, G; Reincke, M; Shapiro, I | 1 |
| Baudin, E; Berdelou, A; Caramella, C; Hescot, S; Leboulleux, S; Lombes, M; Paci, A | 1 |
| Fareau, GG; Lopez, A; Stava, C; Vassilopoulou-Sellin, R | 1 |
| Bang, SM; Beom, SH; Choi, Y; Chung, JH; Kim, JH; Kim, YJ; Lee, JS; Lee, KW; Song, KH; Yang, Y | 1 |
| Avruch, L; Jonker, DJ; Malik, R; Stewart, D; Wells, J; Yarom, N | 1 |
| Ardito, A; Berruti, A; Bracarda, S; Del Buono, S; Ferrero, A; Priola, AM; Rossi, G; Sperone, P; Taberna, E; Terzolo, M | 1 |
| Allolio, B; Arlt, W; Baudin, E; Berruti, A; Beuschlein, F; de la Fouchardière, C; Edgerly, M; Fassnacht, M; Fojo, T; Gelderblom, H; Haak, H; Hahner, S; Hermsen, I; Jarzab, B; Kenn, W; Kroiss, M; Lacroix, A; Leboulleux, S; Mantero, F; Müller, HH; Quinkler, M; Schade-Brittinger, C; Schlumberger, M; Schteingart, DE; Sender, M; Skogseid, B; Sorbye, H; Sperone, P; Stepan, V; Sundin, A; Tabarin, A; Terzolo, M; Torpy, DJ; Weismann, D; Welin, S; Willenberg, HS; Wilmink, H | 1 |
| Keskin, S; Taş, F; Vatansever, S | 1 |
| Doi, H; Hida, S; Oida, T; Souma, T; Takasu, K | 1 |
| Heikkilä, P; Hovi, L; Saarinen-Pihkala, UM; Vettenranta, K; Wikström, S | 1 |
| Iihara, M; Obara, T | 1 |
| Bednarek-Tupikowska, G; Florczak, A; Tupikowski, W | 1 |
| Callefe, LG; Ferman, S; Figueiredo, BC; Lichtvan, LL; Oliveira, BH; Parise, GA; Pianovski, MA; Piovezan, GC; Santana, MH; Stinghen, ST; Voss, SZ; Zancanella, P | 1 |
| Haak, HR; van de Weijer, R; van Ditzhuijsen, CI | 1 |
| Billalabeitia, EG; Carmona-Bayonas, A; Díaz, MP; Gómez, FI; Saura, HP; Soler, IO; Tafalla, MS | 1 |
| Angeli, A; Berruti, A; Dogliotti, L; Pia, A; Terzolo, M | 1 |
| Baker, LH; Balcerzak, SP; Crawford, ED; Lew, D; Miller, GJ; Williamson, SK | 1 |
| Ahlman, H; Jacobsson, CE; Jansson, S; Khorram-Manesh, A; Lindstedt, S; Nilsson, O; Wängberg, B | 1 |
| Abraham, J; Alexander, R; Bakke, S; Bartlett, D; Bates, S; Choyke, P; Fojo, T; Hung, E; Meadows, B; Merino, M; Robey, R; Rutt, A; Schrump, D; Steinberg, SM | 1 |
6 review(s) available for etoposide and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Etoposide; Humans; Mitotane; Neoplasm Recurrence, Local | 2022 |
Next-generation therapies for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Humans; Immunotherapy; Mitotane; Molecular Targeted Therapy; Radiotherapy; Therapies, Investigational | 2020 |
[Diagnosis and treatment for adrenocortical carcinoma].
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cholesterol; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Mitotane; Prognosis; Radionuclide Imaging; Tomography, X-Ray Computed | 2004 |
[Adrenocortical carcinoma and its treatment].
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Humans; Mitotane | 2004 |
Adrenocortical carcinoma.
Topics: Academic Medical Centers; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Doxorubicin; Etoposide; Humans; Internationality; Mitotane; Netherlands; Streptozocin | 2007 |
Cytotoxic treatment of adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Cisplatin; Doxorubicin; Etoposide; Humans; Mitotane | 2001 |
7 trial(s) available for etoposide and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Humans; Middle Aged; Mitotane; Retrospective Studies; Treatment Outcome; Young Adult | 2021 |
Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma.
Topics: Administration, Metronomic; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Treatment Outcome | 2013 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Mitotane; Quality of Life; Streptozocin; Young Adult | 2012 |
Adrenocortical carcinoma in children: a role for etoposide and cisplatin adjuvant therapy? Preliminary report.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Infant; Male | 2003 |
Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
Topics: Administration, Oral; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Male; Mitotane; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2006 |
Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Topics: Administration, Oral; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Leukopenia; Male; Middle Aged; Mitotane; Prospective Studies; Thrombocytopenia; Treatment Outcome | 1998 |
Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Etoposide; Female; Humans; Male; Middle Aged; Mitotane | 2000 |
22 other study(ies) available for etoposide and Adrenocortical Carcinoma
| Article | Year |
|---|---|
ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Datasets as Topic; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Repressor Proteins | 2021 |
[A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Mitotane | 2022 |
Mitotane With or Without Cisplatin and Etoposide for Patients with a High Risk of Recurrence in Stages 1-3 Adrenocortical Cancer After Surgery.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Mitotane | 2023 |
Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Carboplatin; Etoposide; Humans; Male; Mitotane | 2023 |
Case Report: Ectopic Adrenocortical Carcinoma in the Ovary.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Bevacizumab; Cisplatin; Cytoreduction Surgical Procedures; Etoposide; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Ovarian Neoplasms; Ovary | 2021 |
Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Mitotane; Prognosis; Remission Induction; Temozolomide; Young Adult | 2021 |
Long-Term Survival in a Patient With Metastatic DDR2-Positive Adrenal Cortical Carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Carboplatin; Combined Modality Therapy; Discoidin Domain Receptor 2; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Male; Middle Aged; Mitotane; Mutation; Neoplasm Metastasis; Nephrectomy; Tomography Scanners, X-Ray Computed | 2017 |
Long-term survival in recurrent adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bangladesh; Chronic Disease; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Humans; Male; Mitotane; Neoplasm Recurrence, Local; Prognosis; Time Factors; Treatment Outcome | 2019 |
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemoembolization, Therapeutic; Cisplatin; Disease Management; Doxorubicin; Endocrinology; Etoposide; Europe; Humans; Mitotane; Neoplasm Metastasis; Prognosis; Radiotherapy; Societies, Medical | 2018 |
Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Proliferation; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Mitotane; Paclitaxel; Polyethylene Glycols; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Liposomes; Male; Mice; Mice, Nude; Middle Aged; Mitotane; Polyethylene Glycols; Translational Research, Biomedical; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Multi-Target Approach to Metastatic Adrenal Cell Carcinoma.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Laparotomy; Liver Neoplasms; Mitotane; Positron Emission Tomography Computed Tomography | 2016 |
Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Humans; Laparoscopy; Mitotane; Peritoneal Neoplasms; Retrospective Studies | 2016 |
Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Disease Models, Animal; Doxorubicin; ErbB Receptors; Etoposide; Female; Humans; Ki-67 Antigen; Male; Mitotane; Mucin-1; Neoplasm Transplantation; RNA Splicing Factors; Tumor Cells, Cultured; Young Adult | 2016 |
Early progression under mitotane and polychemotherapy does not mean failure in adrenocortical carcinoma patient.
Topics: Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Carboplatin; Drug Therapy, Combination; Etoposide; Female; Humans; Middle Aged; Mitotane; Survival Rate; Treatment Outcome | 2017 |
Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies.
Topics: Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Etoposide; Female; Humans; Male; Middle Aged; Mitotane; Regression Analysis | 2008 |
Metastatic adrenocortical carcinoma presenting simultaneously with Cushing's and Conn's syndromes: a case report.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cushing Syndrome; Doxorubicin; Etoposide; Fatal Outcome; Humans; Hyperaldosteronism; Lung Neoplasms; Male; Mitotane; Pneumonia; Tomography, X-Ray Computed | 2011 |
ADH-1 in the treatment of metastatic adrenocortical carcinoma--case report.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cisplatin; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Humans; Oligopeptides; Peptides, Cyclic; Treatment Outcome; Young Adult | 2011 |
Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Tumor Burden | 2013 |
[A case of adrenal cortical carcinoma].
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Humans; Male | 2002 |
Tailored hormonal therapy in secretory adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Aged; Aldosterone; Alkalosis; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Captopril; Cisplatin; Diarrhea; Doxorubicin; Etoposide; Female; Heart Failure; Humans; Hydrocortisone; Hyperaldosteronism; Hypertension; Hypokalemia; Ketoconazole; Mineralocorticoid Receptor Antagonists; Mitotane; Neoplasm Recurrence, Local; Potassium; Rhabdomyolysis; Spironolactone; Tachycardia | 2007 |
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Topics: Administration, Oral; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; CD56 Antigen; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Mitotane; Neoplasm Metastasis; Rhodamines; Survival Rate; Treatment Outcome; Vincristine | 2002 |